Vertex Teases Launch of Landmark CRISPR Therapy

Vertex Teases Launch of Landmark CRISPR Therapy

Source: 
BioSpace
snippet: 

Vertex Pharmaceuticals is marching toward the launch of exagamglogene autotemcel (exa-cel), its potential one-time treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT) – with a lot of confidence, per its full-year 2022 presentation.